Physician profile
Stephen Parnell
NPI 1609968320
$14,989.47
in general payments reported to CMS, 2019-2025
24 companies · $3,614 in 2025
The $3,614 reported for 2025 was more than what 89% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,271 · 2020: $1,321 · 2021: $2,161 · 2022: $2,591 · 2023: $2,047 · 2024: $1,985 · 2025: $3,614.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,979 · Grant: $1,667.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,979.07 |
| Grant | $1,666.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,986.08 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $3,573.55 | 2019-2025 | Xifaxan, Plenvu, Relistor |
| Madrigal Pharmaceuticals | $1,980.00 | 2024-2025 | Rezdiffra, Resmetirom |
| Pfizer INC. | $1,294.18 | 2019-2025 | |
| Gilead Sciences, INC. | $1,106.24 | 2019-2023 | |
| Janssen Biotech, INC. | $846.99 | 2019-2025 | Stelara, Tremfya, Simponi |
| Celgene Corporation | $452.37 | 2022-2024 | Zeposia |
| Braintree Laboratories, INC. | $379.09 | 2019-2024 | Suflave, Sutab |
| Genzyme Corporation | $251.98 | 2022-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $213.40 | 2019-2024 | Eohilia |
| Redhill Biopharma INC. | $201.16 | 2020-2025 | Talicia |
| Nestle Healthcare Nutrition INC. | $136.71 | 2020-2022 | |
| Qol Medical, LLC | $95.74 | 2021-2022 | |
| Ferring Pharmaceuticals INC. | $93.44 | 2019-2023 | Rebyota, Clenpiq |
| Ardelyx, INC. | $80.69 | 2024 | Ibsrela |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viiv Healthcare Company | $78.46 | 2019 | |
| Shionogi INC | $49.61 | 2019-2020 | |
| Alnylam Pharmaceuticals INC. | $42.55 | 2023-2024 | Amvuttra |
| Regeneron Healthcare Solutions, INC. | $34.15 | 2022 | |
| Celltrion USA INC. | $22.27 | 2025 | Vegzelma |
| Novo Nordisk INC | $20.22 | 2025 | Wegovy |
| Phathom Pharmaceuticals, INC. | $19.94 | 2024 | Voquezna |
| Intercept Pharmaceuticals, INC. | $18.77 | 2020 | |
| Allergan, INC. | $11.88 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Parnell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.